Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
В Москве 11 апреля 2012 г. состоялость заседание экспертного совета по применению нового ингибитора дипептидилпептидазы-4 (ДПП-4) ТРАЖЕНТА (линаглиптин) в лечении сахарного диабета 2 типа (СД2). Планируется, что препарат уже осенью станет доступен для пациентов....
Saved in:
Main Author: | Editorial team Diabetes Mellitus |
---|---|
Format: | article |
Language: | EN RU |
Published: |
Endocrinology Research Centre
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/93f6cdf4065f4e828c8b48e09f0f4ef5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Russian Association of Endocrinologists reports commencement of Trajenta clinical use
by: Editorial team Diabetes Mellitus
Published: (2012) -
Expert committee on introduction of incretin-based therapy in Russia: advance and failure
by: Editorial team Diabetes Mellitus
Published: (2012) -
New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012) -
Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010) -
Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010)